IP Library › Granted Patent US 9,657,041
Granted Patent B2
US 9,657,041 · App. 15/062,872 · Granted May 23, 2017

Chiral aryl or aryl-alkyl phosphoramidate dexamphetamine precursors having a regioisomeric purity >99%

Inventors: Harold Meckler (Delmar, NY); Brian Gregg (Altamont, NY); Jie Yang (Rensselaer, NY)
Assignee: Chemapotheca, LLC
C07F9/2475C07C209/62C07F9/2458C07B2200/07C07F9/564
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,657,041
App. No.
15/062,872
Granted
May 23, 2017
Kind
B2
Abstract

The invention includes processes for the synthesis of amphetamine, dexamphetamine, methamphetamine, derivatives of these, including their salts, and novel precursors and intermediates obtained thereby, by synthesizing aziridine phosphoramidate compounds in specified solvents at specified temperatures, and then converting to a novel aryl or aryl-alkyl phosphoramidate precursors using an organometallic compound such as a copper salt, where the novel aryl or aryl-alkyl phosphoramidate precursor is then easily converted to the target compounds using known reactions.

Claims (17)

1. A process for the synthesis of a chiral aryl or aryl-alkyl phosphoramidate dexamphetamine precursor comprising the steps:

reacting an S-[diaryl- or dialkyl-]-(2-methylaziridin-1-yl)phosphonate compound with phenylmagnesium halide in tetrahydrofuran and a copper catalyst under temperature conditions that range from 25° C. to 80° C. to obtain a chiral aryl or aryl-alkyl phosphoramidate dexamphetamine precursor; and,

performing a solvent crystallization of the chiral aryl or aryl-alkyl phosphoramidate dexamphetamine precursor requiring a mixture of two or more solvents, wherein one of the solvents is residual THF, wherein the chiral aryl or aryl-alkyl phosphoramidate dexamphetamine precursor has a regioisomeric purity >99%;

wherein the copper catalyst is CuCl, CuCl 2 , CuBr CuF, Cu(OAc) 2 , Cu(acac) 2 , Cu(OMe) 2 , Copper turnings or Copper nanoparticles.

2. The process according to claim 1 , wherein said temperature conditions range from 30° C. to 60° C.

3. The process of claim 1 , wherein one of the solvents of the mixture of two or more solvents is tetrahydrofuran (THF).

4. The process of claim 1 , wherein the S-[diaryl- or dialkyl-]-(2-methylaziridin-1-yl)phosphonate compound is a compound of Formula 4:

(Formula 4); wherein R is alkyl or aryl; and,

wherein the chiral aryl or aryl-alkyl phosphoramidate dexamphetamine precursor is a compound of Formula 5:

(Formula 5) wherein R is alkyl or aryl.

5. The process of claim 1 , wherein one of the solvents of the mixture of two or more solvents is heptanes.

6. The process of claim 1 , wherein one of the solvents of the mixture of two or more solvents is an organic ether.

7. The process of claim 1 , wherein one of the solvents of the mixture of two or more solvents is 2-methyl-tetrahydrofuran.

8. The process of claim 1 , wherein one of the solvents of the mixture of two or more solvents is toluene.

9. The process of claim 1 , wherein the S-[diaryl- or dialkyl-]-(2-methylaziridin-1-yl)phosphonate compound is combined with the copper catalyst in tetrahydrofuran, followed by a slow addition of phenylmagnesium halide in THF while temperature is maintained.

10. The process of claim 1 , wherein the obtained chiral aryl or aryl-alkyl phosphoramidate dexamphetamine precursor is washed in heptanes as part of the crystallization step.

11. The process of claim 1 , wherein the mixture of two or more solvents, comprises a combination of MTBE and heptanes.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2016
From: MECKLER, HAROLD; GREGG, BRIAN THOMAS; YANG, JIE
To: CHEMAPOTHECA, LLC
Reel/Frame 040299/0635 →
Continuity (3)
Division 14189630 · Feb 25, 2014
Provisional Application 61922729 · Dec 31, 2013
Related Publication 20160207945A1 · Jul 21, 2016